NFKB1 and breast neoplasm: Besides, the reason underlying 25% of ER-positive breast tumor patients developing NF-κB antagonists’ resistance is due to the constitutive expression and activation of NF-κB members [94], which will eventually lead to estrogen-independent growth [203,204,205].